Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications
| Autor: | Christiane Smerling, Ulrich Reineke, Marvin Stiebler, Annette Pethe, Jörg Schulz, Frank Osterkamp, Holger Amthauer, Oliver S. Grosser, Jürgen Goldschmidt, Martin Rohracker |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Biodistribution Neurotensin receptor 1 Theranostic Nanomedicine Targeted radionuclide therapy Mice Nude Pharmacology Comparative evaluation Mice 03 medical and health sciences chemistry.chemical_compound Cell Line Tumor Animals Humans Receptors Neurotensin Tissue Distribution Radiology Nuclear Medicine and imaging Mice nude Tomography Emission-Computed Single-Photon Chemistry Indium Radioisotopes Neoplasms Experimental 030104 developmental biology Isotope Labeling Pyrazoles Neoplasm Transplantation Ex vivo Neurotensin |
| Zdroj: | Journal of Nuclear Medicine. 57:1120-1123 |
| ISSN: | 2159-662X 0161-5505 |
| DOI: | 10.2967/jnumed.115.170530 |
| Popis: | Neurotensin receptor-1 (NTR1) is a promising target for diagnostic imaging and targeted radionuclide therapy. The aim of this study was to evaluate the biodistribution profiles of a series of newly developed diarylpyrazole-based NTR1 antagonists regarding their suitability as diagnostic and potentially radiotherapeutic agents. Methods: 3BP-227, 3BP-228, and 3BP-483 were labeled with 111In and injected intravenously into NTR1-positive HT29 xenograft–bearing nude mice. At 3, 6, 12, and 24 h after administration, SPECT/CT images were acquired or mice were sacrificed for ex vivo determination of tissue-associated radioactivity. Results: High-contrast tumor visualization in SPECT/CT images was achieved using the 3 compounds of this study. Ex vivo biodistribution studies confirmed a high and persistent tumor uptake, peaking at 6 h after injection for 111In-3BP-227 (8.4 ± 3.1 percentage injected dose per gram [%ID/g]) and at 3 h after injection for 111In-3BP-228 (10.2 ± 5.3 %ID/g) and 111In-3BP-483 (1.9 ± 0.8 %ID/g). Tumor–to–normal-tissue ratios obtained with 111In-3BP-227 and 111In-3BP-228 were consistently greater than 1. Conclusion: On the basis of the superior biodistribution profile compared with previously reported radiolabeled NTR1 ligands, 111In-3BP-227 is an ideal candidate for further development as a theranostic tracer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|